TG Therapeutics Inc.

4 days ago · marketbeat.com

TG Therapeutics NASDAQ: TGTX Chairman, President and Chief Executive Officer Mike Weiss said the company's multiple sclerosis therapy, BRIUMVI, has captured more than one-third of the intravenous anti-CD20 market and continues to gain share as it approaches its fourth full year on the market.

8 days ago · defenseworld.net

California State Teachers Retirement System lifted its holdings in shares of TG Therapeutics, Inc. (NASDAQ: TGTX) by 5,233.8% in the second quarter, according to its most recent filing with the SEC. The firm owned 9,374,083 shares of the biopharmaceutical company's stock after acquiring an additional 9,198,333 shares during the period. California State Teachers

20 days ago · zacks.com

TG Therapeutics (TGTX) reported earnings 30 days ago. What's next for the stock?

27 days ago · seekingalpha.com

TG Therapeutics, Inc.'s Q4 2026/H1 2027 will be rich in catalysts. From the presentation of preliminary Phase 1 azer-cel data in progressive MS in the second half of 2026 to topline Phase 3 data for Briumvi SC by year-end 2026/early 2027. TG Therapeutics raised its Briumvi U.S. net product revenue from $885-$900 million to $890-$905 million.

1 month ago · defenseworld.net

TG Therapeutics, Inc. (NASDAQ: TGTX - Get Free Report) has earned an average rating of "Hold" from the nine brokerages that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the company. The average

2 months ago · seekingalpha.com

TG Therapeutics, Inc. remains a Buy as BRIUMVI's momentum supports a durable, growing multiple sclerosis franchise. TGTX's Q2 saw BRIUMVI revenue surge 64% YoY to $228 million, prompting 2026 guidance to $950 million, though net income was impacted by manufacturing investments. Subcutaneous BRIUMVI, with Phase 3 data expected late 2026 or early 2027, could expand the addressable market and drive future gross margin tailwinds.

2 months ago · zacks.com

TG Therapeutics misses Q2 earnings estimates, but surging Briumvi demand lifts revenues y/y and prompts higher 2026 revenue guidance. Stock falls.

2 months ago · seekingalpha.com

TG Therapeutics, Inc. (TGTX) Q2 2026 Earnings Call Transcript

2 months ago · zacks.com

The headline numbers for TG Therapeutics (TGTX) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

2 months ago · marketbeat.com

TG Therapeutics NASDAQ: TGTX reported second-quarter 2026 revenue of $240 million and raised its full-year sales outlook for BRIUMVI, its treatment for relapsing multiple sclerosis, as the company cited record new patient starts, continued prescriber expansion and higher-than-expected treatment persistence.